Phase I study of an antihyperlipidemic BAY w 6228 (cerivastin sodium) (1): Results on single administration studies in healthy adult male volunteers

Japanese Pharmacology and Therapeutics

Volumn 24, Issue SUPPL. 9, 1996, Pages 29-36

  Azuma, Junichi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID METABOLISM; MALE; PHASE 1 CLINICAL TRIAL; VOLUNTEER;

EID: 0029958467     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Kannel WB et al : Serum cholesterol, lipoproteins and the risk of coronary heart disease. Ann Intern Med 74 : 1-12, 1971
2. Lipid Research Clinics Program : The lipid research clinics coronary primary prevention trial results ( I ) ; Reduction in incidence of coronary heart disease. JAMA 251 : 351-364, 1984
3. Lipid Research Clinics Program : The lipid research clinics coronary primary prevention trial results (II) ; The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251 : 365-374, 1984
4. Frick MH et al : Helsinki heart study ; Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia ; Safety of treatment, changes in risk factors, and incidence of coronary heart disease. W Engl J Med 317 : 1237-1245, 1984
5. Angerbauer R et al : A new generation HMG-CoA reductase inhibitor I. Synthesis and Structure Activity Relationships, XI International Symposium on Drugs Affecting Lipid Metabolism, Florence, Italy, 1992
6. 14C] BAY w 6228 ; Evaluation of the site of absorption in an in vivo rat model. Bayer AG Report No. 22780 A, 1994